

ARGENX SE

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(in thousands of \$)	As of December 31,		
	2021	2020	2019
ASSETS			
Current assets			
Cash and cash equivalents	\$ 1,334,676	\$ 1,216,803	\$ 372,162
Research and development incentive receivables — current	—	463	293
Financial assets — current	1,002,052	779,649	1,128,499
Prepaid expenses	58,946	27,913	10,136
Trade and other receivables	38,221	6,978	31,585
Inventories	109,076	25,195	—
Total current assets	2,542,971	2,057,001	1,542,675
Non-current assets			
Other non-current assets	54,876	7,816	3,624
Research and development incentive receivables — non-current	32,707	20,626	9,624
Deferred tax asset	32,191	15,038	—
Property, plant and equipment	15,844	11,582	9,175
Intangible assets	171,684	167,344	45,117
Total non-current assets	307,303	222,406	67,540
TOTAL ASSETS	\$ 2,850,274	\$ 2,279,407	\$ 1,610,215
EQUITY AND LIABILITIES			
Equity			
Equity attributable to owners of the parent			
<i>Share capital</i>	\$ 6,233	\$ 5,744	\$ 5,209
<i>Share premium</i>	3,462,775	2,339,033	1,505,641
<i>Translation differences</i>	131,684	134,732	(27,541)
<i>Accumulated losses</i>	(1,400,197)	(991,932)	(383,477)
<i>Other reserves</i>	333,729	186,474	80,577
Total equity	\$ 2,534,224	\$ 1,674,051	\$ 1,180,409
Non-current liabilities			
Provisions for employee benefits	417	156	72
Lease liabilities — non-current	7,956	6,181	5,101
Deferred tax liabilities	6,438	1,487	—
Deferred revenue — non-current	—	269,039	244,937
Total non-current liabilities	14,811	276,863	250,110
Current liabilities			
Lease liabilities — current	3,509	3,476	2,218
Trade and other payables	293,415	275,192	95,827
Tax liabilities	4,315	3,497	386
Deferred revenue — current	—	46,328	81,265
Total current liabilities	301,239	328,493	179,696
Total liabilities	\$ 316,050	\$ 605,356	\$ 429,806
TOTAL EQUITY AND LIABILITIES	\$ 2,850,274	\$ 2,279,407	\$ 1,610,215

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

(in thousands of \$ except for shares and EPS)	Year Ended December 31,		
	2021	2020	2019
Revenue	\$ 497,277	\$ 41,243	\$ 78,462
Other operating income	42,141	23,668	15,563
Total operating income	539,418	64,911	94,025
Research and development expenses	(580,520)	(370,885)	(220,771)
Selling, general and administrative expenses	(307,644)	(171,643)	(72,146)
Total operating expenses	(888,164)	(542,528)	(292,917)
Operating loss	\$ (348,746)	\$ (477,617)	\$ (198,892)
Financial income/(expense)	(944)	(1,501)	15,983
Exchange gains/(losses)	(50,053)	(126,234)	6,990
Loss before taxes	\$ (399,743)	\$ (605,352)	\$ (175,919)
Income tax expense	\$ (8,522)	\$ (3,103)	\$ (5,289)
Loss for the year	\$ (408,265)	\$ (608,455)	\$ (181,208)
Loss for the year attributable to:			
Owners of the parent	<u>\$ (408,265)</u>	<u>\$ (608,455)</u>	<u>\$ (181,208)</u>
Weighted average number of shares outstanding	51,075,827	45,410,442	38,619,121
Basic and diluted loss per share (in \$)	(7.99)	(13.40)	(4.69)

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME / LOSS

(in thousands of \$ except for shares)	Year Ended December 31,		
	2021	2020	2019
Loss for the year	\$ (408,265)	\$ (608,455)	\$ (181,208)
Items that may be reclassified subsequently to profit or loss, net of tax			
Currency translation differences, arisen from translating foreign activities	(3,048)	—	—
Translation effect	—	162,273	(8,587)
Items that will not be reclassified subsequently to profit or loss, net of tax			
Fair value gain/(loss) on investments in equity instruments designated as at FVTOCI	(39,290)	—	—
Other comprehensive loss, net of income tax	(42,338)	162,273	(8,587)
Total comprehensive loss attributable to:			
Owners of the parent	<u>\$ (450,603)</u>	<u>\$ (446,182)</u>	<u>\$ (189,795)</u>

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands of \$)	Year Ended December 31,		
	2021	2020	2019
CASH FLOWS (USED IN) / FROM OPERATING ACTIVITIES			
Operating loss	\$ (348,746)	\$ (477,617)	\$ (198,892)
Adjustments for non-cash items			
Amortization of intangible assets	776	246	43
Depreciation of property, plant and equipment	5,091	3,671	2,382
Provisions for employee benefits	260	76	64
Expense recognized in respect of share-based payments	179,366	96,932	44,236
Fair value gains on non-current financial assets at fair value through profit or loss	(11,152)	(2,951)	(1,214)
Non-cash revenue	(75,000)	—	—
	\$ (249,405)	\$ (379,643)	\$ (153,381)
Movements in current assets/liabilities			
(Increase)/decrease in trade and other receivables	(31,632)	21,961	(25,709)
(Increase)/decrease in inventories	(83,880)	(23,852)	—
(Increase)/decrease in other current assets	(30,990)	(16,189)	(5,788)
Increase/(decrease) in trade and other payables	134,892	50,537	53,729
Increase/(decrease) in deferred revenue – current	(46,327)	(40,441)	69,526
Movements in non-current assets/liabilities			
(Increase)/decrease in other non-current assets	(13,975)	(10,299)	(6,224)
(Increase)/decrease in deferred revenue – non-current	(269,039)	2,655	224,492
Cash flows (used in)/from operating activities	(590,356)	(395,272)	156,645
Interest paid	(684)	(401)	(139)
Income taxes paid	(15,772)	(2,791)	(4,876)
NET CASH FLOWS (USED IN) / FROM OPERATING ACTIVITIES	\$ (606,812)	\$ (398,463)	\$ 151,630
Purchase of intangible assets	(117,811)	(4,071)	(44,939)
Purchase of property, plant and equipment	(3,623)	(1,068)	(1,796)
(Increase)/decrease in financial assets – current	(228,239)	341,869	(792,655)
Interest received	2,603	7,962	6,122
NET CASH FLOWS (USED IN) / FROM INVESTING ACTIVITIES	\$ (347,070)	\$ 344,692	\$ (833,267)
Principal elements of lease payments	(3,855)	(2,550)	(1,515)
Proceeds from issue of new shares	1,091,326	813,186	755,641
Issue costs paid	(528)	(613)	(25,747)
Exchange gain from currency conversion on proceeds from issue of new shares	966	68	—
Proceeds from exercise of stock options	33,433	22,912	5,345
NET CASH FLOWS (USED IN) / FROM FINANCING ACTIVITIES	\$ 1,121,342	\$ 833,003	\$ 733,726
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS	\$ 167,460	\$ 779,232	\$ 52,088
Cash and cash equivalents at the beginning of the period	\$ 1,216,803	\$ 372,162	\$ 321,791
Exchange gains/(losses) on cash & cash equivalents	\$ (49,587)	\$ 65,409	\$ (1,717)
Cash and cash equivalents at the end of the period	\$ 1,334,676	\$ 1,216,803	\$ 372,162

ARGENX SE

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(in thousands of \$)	Attributable to owners of the parent					Total equity attributable to owners of the parent	Total equity
	Share capital	Share premium	Accumulated losses	Translation differences	Other reserves		
Balance at January 1, 2019	<u>\$ 4,451</u>	<u>\$ 796,894</u>	<u>\$ (202,270)</u>	<u>\$ (18,954)</u>	<u>\$ 36,341</u>	<u>\$ 616,462</u>	<u>\$ 616,462</u>
Loss for the year			(181,208)			(181,208)	(181,208)
Other comprehensive income / (loss)				(8,587)		(8,587)	(8,587)
Total comprehensive loss of the period			(181,208)	(8,587)		(189,795)	(189,795)
Share-based payment					44,236	44,236	44,236
Issue of share capital	710	756,472				757,182	757,182
Transaction costs for equity issue		(25,476)				(25,476)	(25,476)
Accounting treatment of the share subscription agreement		(27,635)				(27,635)	(27,635)
Exercise of stock options	48	5,386				5,434	5,434
Balance year ended December 31, 2019	<u>\$ 5,209</u>	<u>\$ 1,505,641</u>	<u>\$ (383,477)</u>	<u>\$ (27,541)</u>	<u>\$ 80,577</u>	<u>\$ 1,180,409</u>	<u>\$ 1,180,409</u>
Loss for the year			(608,455)			(608,455)	(608,455)
Other comprehensive income / (loss)				162,273		162,273	162,273
Total comprehensive loss of the period			(608,455)	162,273		(446,182)	(446,182)
Income tax benefit from excess tax deductions related to share-based payments					8,965	8,965	8,965
Share-based payment					96,932	96,932	96,932
Issue of new shares	468	812,718				813,186	813,186
Transaction costs for equity issue		(613)				(613)	(613)
Exercise of stock options	67	21,287				21,354	21,354
Balance year ended December 31, 2020	<u>\$ 5,744</u>	<u>\$ 2,339,033</u>	<u>\$ (991,932)</u>	<u>\$ 134,732</u>	<u>\$ 186,474</u>	<u>\$ 1,674,051</u>	<u>\$ 1,674,051</u>
Loss for the year			(408,265)			(408,265)	(408,265)
Other comprehensive income / (loss)				(3,048)	(39,290)	(42,338)	(42,338)
Total comprehensive loss of the period			(408,265)	(3,048)	(39,290)	(450,603)	(450,603)
Income tax benefit from excess tax deductions related to share-based payments					7,179	7,179	7,179
Share-based payment					179,366	179,366	179,366
Issue of new shares	430	1,090,896				1,091,326	1,091,326
Transaction costs for equity issue		(528)				(528)	(528)
Exercise of stock options	59	33,374				33,433	33,433
Balance year ended December 31, 2021	<u>\$ 6,233</u>	<u>\$ 3,462,775</u>	<u>\$ (1,400,197)</u>	<u>\$ 131,684</u>	<u>\$ 333,729</u>	<u>\$ 2,534,224</u>	<u>\$ 2,534,224</u>